Prime Medicine, Inc. (PRME)

About Prime Medicine, Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

As of November 3, 2026, Prime Medicine, Inc. (PRME) stock climbed to $4.57, up 2.82% (+$0.12) versus the previous close. On the day, shares have traded between $4.50 and $4.88. That puts PRME around the middle of its 52-week range of $2.67 to $5.91. Prime Medicine, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $856.10 million, with about 1.86 million shares changing hands.

Latest PRME news

• Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Yahoo Finance· Oct 29, 2:41 AM ET
• PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Editsstocktwits.com· Oct 28, 3:34 PM ET
• Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyYahoo Finance· Oct 12, 11:24 AM ET
• Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson DiseaseYahoo Finance· Oct 5, 8:00 AM ET
• Temporary Weakness in Intellia Stock Seems Like a Buying Opportunitybarchart.com· Sep 29, 9:00 AM ET
• Prime Medicine stock surges on FDA IND clearanceYahoo Finance· Sep 24, 4:47 PM ET
• Anthropic AI Discovery Gene-Editing Stocks FallingYahoo Finance· Sep 24, 8:46 AM ET
• CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?stocktwits.com· Sep 23, 5:49 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want PRME headlines, alerts and AI research in one place? Create a free account →

• $PRME Prime Medicine, Inc. (NASDAQ: PRME) has cleared a legal obstacle and advanced two gene-editing programs. Here is what investors should watch as clinical progress meets funding pressure. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-prime-medicine…

  @BioTechHealthX· Nov 3, 12:46 PM ET

• $PRME entry on the close yesterday, bank participation today 💎💎💎💎

  @Alien1980· Nov 3, 9:46 AM ET· Bullish

• $PRME bounced off 9 D EMA, this beast is flying under the radar

  @Blankbeanie· Nov 3, 9:41 AM ET· Bullish

• $PRME Got some bids placed for December $5C’s. Just profit money, don’t be stupid like me.

  @PorkchopSquats· Nov 2, 1:34 PM ET

• $PRME The drop is across the board - NTLA, CRSP, BEAM, EDIT. What these guys have special is of course their impending money raise - whether it's a deal or a dilution is probably the biggest short term driver after the sector and global trends. Given the leverage these day…

  @quark_n_jaguar· Nov 2, 12:14 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →